The Antioxidant Tetrapeptide Epitalon Enhances Delayed Wound Healing in an in Vitro Model of Diabetic Retinopathy.
Level 5 - mechanism / opinion, no new human data
In vitro laboratory study using an established cell line
PubMed 40493162 · doi:10.1007/s12015-025-10911-x
What was done
Researchers investigated whether the synthetic tetrapeptide Epitalon (Ala-Glu-Asp-Gly) could improve delayed wound healing in a high-glucose cell culture model of diabetic retinopathy using the ARPE-19 human retinal pigment epithelial cell line. They evaluated cell wound healing, intracellular reactive oxygen species (ROS) levels, antioxidant gene expression, epithelial-mesenchymal transition (EMT), and fibrosis-related gene expression under high-glucose conditions with and without Epitalon.
What was found
The abstract reports no numerical values, effect sizes, statistical measures, or peptide concentrations. High-glucose exposure delayed ARPE-19 wound healing, elevated intracellular ROS, decreased antioxidant gene expression, and upregulated EMT and fibrosis-related genes. Epitalon treatment reversed the delayed wound healing and suppressed high-glucose-induced EMT and fibrosis markers.
Why it matters
This study provides mechanistic cell culture evidence that Epitalon can counteract high-glucose-induced oxidative stress and fibrosis pathways relevant to proliferative diabetic retinopathy.
Limits
The study is restricted to an in vitro model using a single cell line (ARPE-19), which lacks the vascular, neural, and systemic complexity of in vivo diabetic retinopathy. No quantitative metrics, concentrations, durations, or sample replicates are reported in the abstract. Clinical efficacy, safety, and ocular pharmacokinetics remain unstudied.
Cited by
- supports Epitalon is a tetrapeptide with the amino acid sequence Ala-Glu-Asp-Gly (AEDG).